The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG.BrusamolinoE.ValagussaP.Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med.1976; 294: 405–410.
2.
CoombesR.C.BlissJ.M.WilsJ.Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol.1996; 14: 35–45.
3.
LevineM.N.BramwellV.PritchardL.A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node-positive or locally advanced breast cancer. Eur J Cancer.1993; 29: 37–43.
4.
LevineM.N.BramwellV.H.PritchardKlRandomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol.1998; 16(8): 2651–2658.
5.
Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. J Clin Oncol.1988; 6(6): 976–982.
6.
French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol.1988; 6(4): 679–688.
7.
TortiF.M.BristowM.M.LumB.L.Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res.1986; 46: 3722–3727.
8.
KirtiK.CasperE.S.GellerN.A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol.1985; 3: 818–826.
9.
CersosimoR.J.HongW.K.Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol.1986; 4: 425–439.
10.
CoukellA.J.FauldsD.Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs.1997; 53: 453–482.
11.
MbueJ.E.SolimandoD.A.WaddellJ.A.Cancer chemotherapy update: fluorouracil, epirubicin and cyclophosphamide (FEC) for breast cancer. Hosp Pharm.2008; 43(6): 462–469.
12.
BaeE.J.SolimandoD.A.WaddellJ.A.Cancer chemotherapy update: flurouracil, epirubicin, and cyclophosphamide (FEC100) for breast cancer. Hosp Pharm.2009; 44(1): 26–33.
13.
LevineM.N.PritchardK.I.BramwellV.H.Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada clinical trials group trial MA5. J Clin Oncol.2005; 23(22): 5166–5170.
14.
BurnellM.LevineM.N.ChapmanJ.W.Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol.2010; 28(1): 77–82.
15.
TherasseP.MauriacL.Welnicka-JaskiewiczM.Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol.2003; 21(5): 843–850.
16.
LevineN.M.BramwellV.PritchardK.The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamde in patients with early stage breast cancer. Drugs.1003; 45(suppl 2): 51–59.
17.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. V.1.2012. NCCN Web site, http://www.nccn.org. Accessed March 8, 2012.
18.
HeskethP.J.KrisM.G.GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
BaschE.PrestrudA.A.HeskethP.J.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2011. J Clin Oncol.2011; 29: 4189–4198.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
23.
BeckT.M.The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs.1995; 6(2): 237–242.
24.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
25.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
26.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
27.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19;85(8): 1099–1101.
28.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
29.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
30.
StillwellT.J.BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–457.
31.
MonachP.A.ArnoldL.M.MerkelP.A.Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic disease. Arthritis Rheum.2010; 62(1): 9–21.
ZanottiK.M.MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
34.
SmithT.J.KhatcheressianJ.LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
37.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–402.
38.
MullinS.BeckwithM.C.TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
39.
MarounJ.A.AnthonyL.B.BiaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
40.
BensonA.B.AjaniJ.A.CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
AronoffG.R.BennettW.M.BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
43.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
44.
FloydJ.MirzaI.SachsPerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
45.
DobbsN.A.TwelvesC.J.GregoryW.CruickshankaC.RichardsM.A.RubensR.D.Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer2003; 39(5): 580–586.
46.
KingP.D.Perry MC. Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
